PURETECH HEALTH PLC - ADR (PRTC) Stock News

USA - Nasdaq - NASDAQ:PRTC - US7462371060 - ADR

16.75 USD

-1.3 (-7.2%)

Last: 12/8/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PRTC Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: PureTech Health plc

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

4 days ago - By: PureTech Health plc

PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

a month ago - By: PureTech Health plc

PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting

2 months ago - By: PureTech Health plc

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

2 months ago - By: PureTech Health plc

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

3 months ago - By: The Motley Fool

PureTech Health Cash Runway Extended

7 months ago - By: Benzinga - Mentions: AVB CMPR PPL LANC ...

Earnings Scheduled For April 30, 2025

3 months ago - By: Benzinga - Mentions: WYFI SERV B FDX ...

CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday

3 months ago - By: PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers

3 months ago - By: The Motley Fool

PureTech (PRTC) Q2 2025 Earnings Call Transcript

3 months ago - By: PureTech Health plc

PureTech Health plc – Half-Year Report

4 months ago - By: PureTech Health plc

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

4 months ago - By: PureTech Health plc

PureTech Health: Notice of Half-Yearly Results

4 months ago - By: PureTech Health plc

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

4 months ago - By: PureTech Health plc

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

5 months ago - By: PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

5 months ago - By: PureTech Health plc

PureTech Announces Leadership Transition

5 months ago - By: PureTech Health plc

PureTech Announces Board Change

6 months ago - By: PureTech Health plc

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement

6 months ago - By: PureTech Health plc

PureTech Health: Results of Annual General Meeting

7 months ago - By: PureTech Health plc

PureTech to Present at the Jefferies Global Healthcare Conference

7 months ago - By: PureTech

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

7 months ago - By: PureTech Health plc

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

7 months ago - By: PureTech Health plc

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

7 months ago - By: PureTech Health plc

PureTech Announces Annual Results for Year Ended December 31, 2024

8 months ago - By: PureTech Health plc

PureTech Health: Notice of Results

8 months ago - By: PureTech Health plc

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

8 months ago - By: PureTech Health plc

PureTech Health plc Statement Regarding Press Speculation

9 months ago - By: PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

10 months ago - By: PureTech Health plc

PureTech to Present at the Leerink Partners Global Healthcare Conference

10 months ago - By: PureTech Health plc

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform